BIGBEAR
PHARMACEUTICALS
Cabozantinib is an oral multi-targeted tyrosine kinase inhibitor with broad-spectrum anticancer activity.
AuthenticGuaranteeFast DeliveryPrivacy On March 26, 2025, Exelixis announced that the U.S. Food and Drug Administration (FDA) has approved cabozantinib (Cabometyx) for the treatment of two ···【Read More】
Update: 05 Mar,2026Source: Haiou HealthViews: 71
On March 26, 2025, Exelixis announced that the U.S. Food and Drug Administration (FDA) has approved cabozantinib (Cabometyx) for the treatment of two ···【Read More】
Update: 28 Feb,2026Source: Haiou HealthViews: 70
Copyright2024@ BIGBEAR All right reserved BIGBEAR
